Katherine Griffiths
The science needed to get adults to grow new stem cells is still years away. But when it happens, it will be a major medical breakthrough, as the brain and other organs will be able to repair themselves after damage. Britain's ReNeuron is at the forefront of the experiments which should mean we one day get there.
The Guildford-based company has had a rocky history with the stock market. It was floated, taken private and then re-floated. The shares trade at 37½p.
Next year will be key for ReNeuron. It has applied for a licence in the US to begin the first trial in humans using stem cells to repair brain damage after strokes.
ReNeuron is worth a fraction of US companies working in the same area. Some analysts believe it is still too early to invest in this sector. Certainly, those putting money into it should do so on a three or four-year view. For those with an appetite for risk, this is a maiden New Year selection for the Business section.
Intercorp Excelle stock quotes
Intercorp Excelle stock charts
Follow this thread
